ATE140483T1 - Natürlicher killerzellen-stimulationsfaktor - Google Patents

Natürlicher killerzellen-stimulationsfaktor

Info

Publication number
ATE140483T1
ATE140483T1 AT90901161T AT90901161T ATE140483T1 AT E140483 T1 ATE140483 T1 AT E140483T1 AT 90901161 T AT90901161 T AT 90901161T AT 90901161 T AT90901161 T AT 90901161T AT E140483 T1 ATE140483 T1 AT E140483T1
Authority
AT
Austria
Prior art keywords
natural killer
killer cell
cell stimulation
stimulation factor
factor
Prior art date
Application number
AT90901161T
Other languages
English (en)
Inventor
Giorgio Trinchieri
Bice Perussia
Michiko Kobayashi
Steven C Clark
Gordon G Wong
Rodney M Hewick
Original Assignee
Genetics Inst
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst, Wistar Inst filed Critical Genetics Inst
Application granted granted Critical
Publication of ATE140483T1 publication Critical patent/ATE140483T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT90901161T 1988-11-10 1989-11-09 Natürlicher killerzellen-stimulationsfaktor ATE140483T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26994588A 1988-11-10 1988-11-10
US30781789A 1989-02-07 1989-02-07

Publications (1)

Publication Number Publication Date
ATE140483T1 true ATE140483T1 (de) 1996-08-15

Family

ID=26953989

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90901161T ATE140483T1 (de) 1988-11-10 1989-11-09 Natürlicher killerzellen-stimulationsfaktor

Country Status (8)

Country Link
EP (1) EP0441900B1 (de)
JP (3) JP2893653B2 (de)
AT (1) ATE140483T1 (de)
AU (1) AU638430B2 (de)
CA (2) CA2002607C (de)
DE (1) DE68926859T2 (de)
MX (1) MX9203294A (de)
WO (1) WO1990005147A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
ATE369383T1 (de) * 1989-12-22 2007-08-15 Hoffmann La Roche Monoklonale antikörper spezifisch für den zytotoxischen lymphozyten-reifefaktor
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
WO1994012519A1 (en) * 1992-11-25 1994-06-09 Brigham And Women's Hospital Epstein barr virus induced genes
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
US5674483A (en) * 1995-01-31 1997-10-07 National Jewish Medical And Research Center Treatment for diseases involving inflammation
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Ｉｌ−１２用処方
US5891680A (en) * 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US6372208B1 (en) 1999-09-28 2002-04-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US5652224A (en) 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US6251957B1 (en) 1995-02-24 2001-06-26 Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
EP1649868A1 (de) 1996-05-31 2006-04-26 National University of Ireland, Maynooth IL-12 als Adjuvans für Bordetella pertussis Impfstoffe
WO1998017689A2 (en) * 1996-10-18 1998-04-30 Valentis Inc. Il-12 gene expression and delivery systems and uses
CA2268276A1 (en) * 1996-10-18 1998-04-30 Jeff Nordstrom Gene expression and delivery systems and uses
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
WO1998041229A1 (en) * 1997-03-19 1998-09-24 F. Hoffmann-La Roche Ag USE OF IL-12p40 AS IMMUNOSTIMULANT
US7026456B1 (en) 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
EP1030680A4 (de) 1998-09-15 2003-05-02 Genetics Inst Behandlung von kaposisarkom mit il-12
US6375944B1 (en) 1998-09-25 2002-04-23 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
HUP0201220A3 (en) 1999-05-13 2004-07-28 Wyeth Holdings Corp Madison Adjuvant combination formulations
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
JP2002045174A (ja) * 2000-07-31 2002-02-12 Inst Of Physical & Chemical Res ナチュラルキラー細胞増殖法
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
CZ20031225A3 (cs) 2000-11-10 2003-10-15 Wyeth Holdings Corporation Adjuvantní kombinované prostředky
CA2493487C (en) 2002-08-06 2013-01-22 Aventis Pharma Deutschland Gmbh Method for isolating an intestinal cholesterol binding protein
KR20070094927A (ko) 2004-12-21 2007-09-27 센토코 인코포레이티드 항-ｉｌ-12 항체, 에피토프, 조성물, 방법 및 용도
US9849087B2 (en) 2011-11-08 2017-12-26 The Board Of Trustees Of The University Of Arkansas Methods and compositions for X-ray induced release from pH sensitive liposomes
AU2017241776A1 (en) 2016-03-29 2018-10-11 Janssen Biotech, Inc. Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US11578124B2 (en) 2018-05-18 2023-02-14 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-IL12/IL23 antibody
DK3883606T5 (da) 2018-09-24 2024-01-02 Janssen Biotech Inc Sikker og effektiv fremgangsmåde til behandling af colitis ulcerosa med anti-il12/il23-antistof
JP2022534020A (ja) 2019-05-23 2022-07-27 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473555A (en) * 1983-10-17 1984-09-25 Syntex (U.S.A.) Inc. Nona- and dodecapeptides for augmenting natural killer cell activity
US5185431A (en) * 1988-08-31 1993-02-09 Eisai Co., Ltd. Recombinant natural killer cell activator

Also Published As

Publication number Publication date
WO1990005147A1 (en) 1990-05-17
CA2002607C (en) 2004-01-27
MX9203294A (es) 1992-07-01
JP3261124B2 (ja) 2002-02-25
AU638430B2 (en) 1993-07-01
CA2441636A1 (en) 1990-05-10
JP2001245678A (ja) 2001-09-11
EP0441900B1 (de) 1996-07-17
CA2002607A1 (en) 1990-05-10
EP0441900A1 (de) 1991-08-21
DE68926859D1 (de) 1996-08-22
DE68926859T2 (de) 1997-02-13
JP2893653B2 (ja) 1999-05-24
JPH04502151A (ja) 1992-04-16
JPH11215993A (ja) 1999-08-10
AU4667389A (en) 1990-05-28

Similar Documents

Publication Publication Date Title
DE68926859D1 (de) Natürlicher killerzellen-stimulationsfaktor
DK293689D0 (da) Indretning i en justerbar stol
IT8812558A0 (it) Poltrona per abbronzatura
DK203187A (da) Human g-csf proteinekspression
ATE122357T1 (de) Polypeptide mit hormonwachstumsbefreiender wirkung.
DE3672924D1 (de) Cystein verminderte muteine von biologisch aktiven menschlichen tnf-proteinen.
ZA872705B (en) Human g-csf protein expression
DE69008516T2 (de) In ein lebewesen implantierbares elektromedizinisches gerät.
DK486587D0 (da) Gen, kodende for humane kolonistimulerende faktorer
NO873534L (no) Stabilt farmasoeytisk gelpreparat.
DK551187D0 (da) Terapeutisk praeparat og dettes fremstilling
EP0245433A4 (de) Wichtigstes protein von neisseria gonorrhöe mit eisenregelung und dessen verwendung.
DK209188A (da) Bifunktionelle proteiner, deres fremstilling og anvendelse som laegemiddel
DE3789559T2 (de) Menschlicher präproinsulinähnlicher Wachstumsfaktor I.
DE3682229D1 (de) Zur stimulierung der traenensekretion verwendbare pharmazeutische praeparate.
IT8619457A1 (it) Derivati insaturi cicloalifatici, loro procedimenti di preparazione e loro impiego in terapia e in cosmetica
IT8809003A0 (it) Supporto terapeutico per lungodegenti
DK484489A (da) Regulerbar stol
NO884613L (no) Human interleukin-3- og muteiner derav.
JO1209B1 (en) Pharmacy formulations that include human insulin and the human insulin component.
SE8802685D0 (sv) Stol
NO883982D0 (no) Stillbar stol.
BR8306870A (pt) Valvula cardiaca mecanica implantavel em seres humanos
DE3883397T2 (de) Menschliche insulinanalage und zubereitungen daraus.
ATE54941T1 (de) Cystein verminderte muteine von biologisch aktiven menschlichen tnf-proteinen.

Legal Events

Date Code Title Description
EEFA Change of the company name
EELA Cancelled due to lapse of time